Global Biopharmaceutical Contract Manufacturing Market, 2012 to 2023
Biopharmaceutical Contract Manufacturing Market
Biopharmaceuticals are also known as biologics. Biopharmaceutical products are pharmaceutical drugs that are synthesized, processed, or extracted from biological sources. Biopharmaceuticals include vaccines, blood products, recombinant therapeutic proteins, allergens, gene therapies, tissues and living cells used in cell therapy. Many companies outsource the manufacturing of biopharmaceuticals due to lack of manufacturing capabilities or in order to reduce the cost of manufacture process.Contract manufacturing organizations offer a wide range of services such as cell line development, process optimization, fermentation biotechnology, analytical characterization, cGMP manufacturing, and validation in each stage of clinical development and commercialization.
Biopharmaceutical contract manufacturing market is mainly driven by increase in investment of the pharma and biotechnological companies to develop and commercialize the biotechnological products. In addition, high revenue generation of blockbuster biological drugs such as humira, rituxan, lantus, avastin, herceptin and remicade are gaining traction from many biologics manufacturers. Advancements in the biotechnology such as recombinant DNA technologies and targeted drug therapies are expected to bolster the biopharmaceutical contract manufacturing market over the forecast period. Furthermore, to meet demand for biological products, companies are outsourcing the biopharmaceutical manufacturing to various contract manufacturing companies. However, high cost associated with manufacture and stringent regulatory requirements are expected to hamper the growth of biopharmaceutical contract manufacturing market.
Biopharmaceutical contract manufacturing market segmented based on manufacturing process, type of services, molecule type and end user
Based on manufacturing process, biopharmaceutical contract manufacturing market is segmented into
Mammalian Based
Microbial Based
Insect Based
Plant Based
Yeast Based
Others
Based on type of service, biopharmaceutical contract manufacturing market is segmented into
Formulation
Fill and Finish services
Cell Banking
Analytical Services
Process development
Others
Based on molecule type, biopharmaceutical contract manufacturing market is segmented into
Large Molecules
Small Molecules
Based on end-user, biopharmaceutical contract manufacturing market is segmented into
Biopharmaceutical Companies
Pharmaceutical Companies
Research Organizations
Others
Global biopharmaceutical contract manufacturing market is expected to grow at a significant rate during the forecast period. The market is highly competitive where the speed to market is imperative along with efficient process and low costs. Biopharmaceutical contract manufacturing services providers are increasing their service offerings such as formulation, production and analytical services apart from conventional services to provide complete support for biopharmaceutical companies. Cost considerations and quick services are expected continue to drive the outsourcing of biopharmaceutical contract manufacturing market. In May 2017, Lonza Group Ltd. acquired cell and gene contract manufacturer PharmaCell B.V., this acquisition broadens Lonza’s capabilities in Europe region. Companies expanding the manufacturing facilities to increase market share. For instance, In May 2017, Boehringer Ingelheim GmbH started a new manufacturing facility in China to increase their manufacturing capacity. Through this facility company’s manufacturing capacity will increase by one-third.
Geographically biopharmaceutical contract manufacturing market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to be leading in biopharmaceutical contract manufacturing owing to increased approvals of biosimilars and increase in biopharmaceutical research organization which are lack of manufacturing facilities. In Asia-Pacific region, emerging countries such as China and India expected to grow at a rapid rate owing to low cost of manufacturing. Development of biologics pipeline by domestic companies expected to drive the growth of biopharmaceutical contract manufacturing in China.
Some of the players in biopharmaceutical contract manufacturing market are Lonza Group Ltd. (Switzerland), Boehringer Ingelheim GmbH (Germany), Charles River Laboratories, Inc. (U.S), Novartis AG (Switzerland) WuXi AppTec Group (China), Rentschler Biotechnologie GmbH (Germany), Fujifilm Holdings Corporation (Japan), Celonic AG (Switzerland), BIOMEVA GmbH (Germany), and ProBioGen AG (Germany) to name a few.
In June 2016, Moderna Therapeutics and Charles River Laboratories International, Inc., an early-stage contract research organization (CRO), are collaborated to support Moderna’s nonclinical discovery and development efforts.
Report Outline:
The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Biopharmaceuticals are also known as biologics. Biopharmaceutical products are pharmaceutical drugs that are synthesized, processed, or extracted from biological sources. Biopharmaceuticals include vaccines, blood products, recombinant therapeutic proteins, allergens, gene therapies, tissues and living cells used in cell therapy. Many companies outsource the manufacturing of biopharmaceuticals due to lack of manufacturing capabilities or in order to reduce the cost of manufacture process.Contract manufacturing organizations offer a wide range of services such as cell line development, process optimization, fermentation biotechnology, analytical characterization, cGMP manufacturing, and validation in each stage of clinical development and commercialization.
Biopharmaceutical contract manufacturing market is mainly driven by increase in investment of the pharma and biotechnological companies to develop and commercialize the biotechnological products. In addition, high revenue generation of blockbuster biological drugs such as humira, rituxan, lantus, avastin, herceptin and remicade are gaining traction from many biologics manufacturers. Advancements in the biotechnology such as recombinant DNA technologies and targeted drug therapies are expected to bolster the biopharmaceutical contract manufacturing market over the forecast period. Furthermore, to meet demand for biological products, companies are outsourcing the biopharmaceutical manufacturing to various contract manufacturing companies. However, high cost associated with manufacture and stringent regulatory requirements are expected to hamper the growth of biopharmaceutical contract manufacturing market.
Biopharmaceutical contract manufacturing market segmented based on manufacturing process, type of services, molecule type and end user
Based on manufacturing process, biopharmaceutical contract manufacturing market is segmented into
Mammalian Based
Microbial Based
Insect Based
Plant Based
Yeast Based
Others
Based on type of service, biopharmaceutical contract manufacturing market is segmented into
Formulation
Fill and Finish services
Cell Banking
Analytical Services
Process development
Others
Based on molecule type, biopharmaceutical contract manufacturing market is segmented into
Large Molecules
Small Molecules
Based on end-user, biopharmaceutical contract manufacturing market is segmented into
Biopharmaceutical Companies
Pharmaceutical Companies
Research Organizations
Others
Global biopharmaceutical contract manufacturing market is expected to grow at a significant rate during the forecast period. The market is highly competitive where the speed to market is imperative along with efficient process and low costs. Biopharmaceutical contract manufacturing services providers are increasing their service offerings such as formulation, production and analytical services apart from conventional services to provide complete support for biopharmaceutical companies. Cost considerations and quick services are expected continue to drive the outsourcing of biopharmaceutical contract manufacturing market. In May 2017, Lonza Group Ltd. acquired cell and gene contract manufacturer PharmaCell B.V., this acquisition broadens Lonza’s capabilities in Europe region. Companies expanding the manufacturing facilities to increase market share. For instance, In May 2017, Boehringer Ingelheim GmbH started a new manufacturing facility in China to increase their manufacturing capacity. Through this facility company’s manufacturing capacity will increase by one-third.
Geographically biopharmaceutical contract manufacturing market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to be leading in biopharmaceutical contract manufacturing owing to increased approvals of biosimilars and increase in biopharmaceutical research organization which are lack of manufacturing facilities. In Asia-Pacific region, emerging countries such as China and India expected to grow at a rapid rate owing to low cost of manufacturing. Development of biologics pipeline by domestic companies expected to drive the growth of biopharmaceutical contract manufacturing in China.
Some of the players in biopharmaceutical contract manufacturing market are Lonza Group Ltd. (Switzerland), Boehringer Ingelheim GmbH (Germany), Charles River Laboratories, Inc. (U.S), Novartis AG (Switzerland) WuXi AppTec Group (China), Rentschler Biotechnologie GmbH (Germany), Fujifilm Holdings Corporation (Japan), Celonic AG (Switzerland), BIOMEVA GmbH (Germany), and ProBioGen AG (Germany) to name a few.
In June 2016, Moderna Therapeutics and Charles River Laboratories International, Inc., an early-stage contract research organization (CRO), are collaborated to support Moderna’s nonclinical discovery and development efforts.
Report Outline:
The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY
2. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET INTRODUCTION
2.1. Global Biopharmaceutical Contract Manufacturing Market – Taxonomy
2.2. Global Biopharmaceutical Contract Manufacturing Market –Definitions
2.2.1. Manufacturing Process
2.2.2. Type of Service
2.2.3. Molecule Type
2.2.4. End-Use Type
3. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Biopharmaceutical Contract Manufacturing Market Dynamic Factors - Impact Analysis
3.6. Global Biopharmaceutical Contract Manufacturing Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Biopharmaceutical Contract Manufacturing Market –Trends
4. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MANUFACTURING PROCESS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Mammalian Based
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Microbial Based
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Insect Based
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Plant Based
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Yeast Based
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FORECAST, BY TYPE OF SERVICE, 2012 - 2016 AND FORECAST, 2017 – 2023
6.1. Formulation
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Fill and Finish services
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Cell Banking
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Analytical Services
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Process development
6.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FORECAST, BY MOLECULE TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Large Molecules
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Small Molecules
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FORECAST, BY END - USE, 2012 - 2016 AND FORECAST, 2017 – 2023
8.1. Biopharmaceutical Companies
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Pharmaceutical Companies
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Research Organizations
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Others
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
9. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. North America
9.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, By Manufacturing Process, By Type of Service, By Molecule Type, By End - Use and Region, 2017 – 2023
10. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Mammalian Based
10.1.2. Microbial Based
10.1.3. Insect Based
10.1.4. Plant Based
10.1.5. Yeast Based
10.1.6. Others
10.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Formulation
10.2.2. Fill and Finish services
10.2.3. Cell Banking
10.2.4. Analytical Services
10.2.5. Process development
10.2.6. Others
10.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Large Molecules
10.3.2. Small Molecules
10.4. End -Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.4.1. Biopharmaceutical Companies
10.4.2. Pharmaceutical Companies
10.4.3. Research Organizations
10.4.4. Others
10.5. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
10.7. North America Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
11. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Mammalian Based
11.1.2. Microbial Based
11.1.3. Insect Based
11.1.4. Plant Based
11.1.5. Yeast Based
11.1.6. Others
11.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Formulation
11.2.2. Fill and Finish services
11.2.3. Cell Banking
11.2.4. Analytical Services
11.2.5. Process development
11.2.6. Others
11.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Large Molecules
11.3.2. Small Molecules
11.4. End - Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.4.1. Biopharmaceutical Companies
11.4.2. Pharmaceutical Companies
11.4.3. Research Organizations
11.4.4. Others
11.5. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, , By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
11.7. Europe Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
12. ASIA-PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Mammalian Based
12.1.2. Microbial Based
12.1.3. Insect Based
12.1.4. Plant Based
12.1.5. Yeast Based
12.1.6. Others
12.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Formulation
12.2.2. Fill and Finish services
12.2.3. Cell Banking
12.2.4. Analytical Services
12.2.5. Process development
12.2.6. Others
12.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Large Molecules
12.3.2. Small Molecules
12.4. End -Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.4.1. Biopharmaceutical Companies
12.4.2. Pharmaceutical Companies
12.4.3. Research Organizations
12.4.4. Others
12.5. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, , By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
12.7. Asia-Pacific Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
13. LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Mammalian Based
13.1.2. Microbial Based
13.1.3. Insect Based
13.1.4. Plant Based
13.1.5. Yeast Based
13.1.6. Others
13.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Formulation
13.2.2. Fill and Finish services
13.2.3. Cell Banking
13.2.4. Analytical Services
13.2.5. Process development
13.2.6. Others
13.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Large Molecules
13.3.2. Small Molecules
13.4. End -Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Biopharmaceutical Companies
13.4.2. Pharmaceutical Companies
13.4.3. Research Organizations
13.4.4. Others
13.5. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, , By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
13.7. Latin America Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
14.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Mammalian Based
14.1.2. Microbial Based
14.1.3. Insect Based
14.1.4. Plant Based
14.1.5. Yeast Based
14.1.6. Others
14.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Formulation
14.2.2. Fill and Finish services
14.2.3. Cell Banking
14.2.4. Analytical Services
14.2.5. Process development
14.2.6. Others
14.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.3.1. Large Molecules
14.3.2. Small Molecules
14.4. End -Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.4.1. Biopharmaceutical Companies
14.4.2. Pharmaceutical Companies
14.4.3. Research Organizations
14.4.4. Others
14.5. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, , By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
14.7. MEA Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Lonza Group Ltd. (Switzerland)
15.2.2. Boehringer Ingelheim GmbH (Germany)
15.2.3. Charles River Laboratories, Inc. (U.S)
15.2.4. Novartis AG (Switzerland)
15.2.5. WuXi AppTec Group (China)
15.2.6. Rentschler Biotechnologie GmbH (Germany)
15.2.7. Fujifilm Holdings Corporation (Japan)
15.2.8. Celonic AG (Switzerland)
15.2.9. BIOMEVA GmbH (Germany)
15.2.10. ProBioGen AG (Germany)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET INTRODUCTION
2.1. Global Biopharmaceutical Contract Manufacturing Market – Taxonomy
2.2. Global Biopharmaceutical Contract Manufacturing Market –Definitions
2.2.1. Manufacturing Process
2.2.2. Type of Service
2.2.3. Molecule Type
2.2.4. End-Use Type
3. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Biopharmaceutical Contract Manufacturing Market Dynamic Factors - Impact Analysis
3.6. Global Biopharmaceutical Contract Manufacturing Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Biopharmaceutical Contract Manufacturing Market –Trends
4. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MANUFACTURING PROCESS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Mammalian Based
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Microbial Based
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Insect Based
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Plant Based
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Yeast Based
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FORECAST, BY TYPE OF SERVICE, 2012 - 2016 AND FORECAST, 2017 – 2023
6.1. Formulation
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Fill and Finish services
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Cell Banking
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Analytical Services
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Process development
6.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FORECAST, BY MOLECULE TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Large Molecules
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Small Molecules
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FORECAST, BY END - USE, 2012 - 2016 AND FORECAST, 2017 – 2023
8.1. Biopharmaceutical Companies
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Pharmaceutical Companies
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Research Organizations
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Others
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
9. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. North America
9.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, By Manufacturing Process, By Type of Service, By Molecule Type, By End - Use and Region, 2017 – 2023
10. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Mammalian Based
10.1.2. Microbial Based
10.1.3. Insect Based
10.1.4. Plant Based
10.1.5. Yeast Based
10.1.6. Others
10.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Formulation
10.2.2. Fill and Finish services
10.2.3. Cell Banking
10.2.4. Analytical Services
10.2.5. Process development
10.2.6. Others
10.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Large Molecules
10.3.2. Small Molecules
10.4. End -Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.4.1. Biopharmaceutical Companies
10.4.2. Pharmaceutical Companies
10.4.3. Research Organizations
10.4.4. Others
10.5. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
10.7. North America Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
11. EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Mammalian Based
11.1.2. Microbial Based
11.1.3. Insect Based
11.1.4. Plant Based
11.1.5. Yeast Based
11.1.6. Others
11.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Formulation
11.2.2. Fill and Finish services
11.2.3. Cell Banking
11.2.4. Analytical Services
11.2.5. Process development
11.2.6. Others
11.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Large Molecules
11.3.2. Small Molecules
11.4. End - Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.4.1. Biopharmaceutical Companies
11.4.2. Pharmaceutical Companies
11.4.3. Research Organizations
11.4.4. Others
11.5. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, , By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
11.7. Europe Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
12. ASIA-PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Mammalian Based
12.1.2. Microbial Based
12.1.3. Insect Based
12.1.4. Plant Based
12.1.5. Yeast Based
12.1.6. Others
12.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Formulation
12.2.2. Fill and Finish services
12.2.3. Cell Banking
12.2.4. Analytical Services
12.2.5. Process development
12.2.6. Others
12.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Large Molecules
12.3.2. Small Molecules
12.4. End -Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.4.1. Biopharmaceutical Companies
12.4.2. Pharmaceutical Companies
12.4.3. Research Organizations
12.4.4. Others
12.5. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, , By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
12.7. Asia-Pacific Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
13. LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Mammalian Based
13.1.2. Microbial Based
13.1.3. Insect Based
13.1.4. Plant Based
13.1.5. Yeast Based
13.1.6. Others
13.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Formulation
13.2.2. Fill and Finish services
13.2.3. Cell Banking
13.2.4. Analytical Services
13.2.5. Process development
13.2.6. Others
13.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Large Molecules
13.3.2. Small Molecules
13.4. End -Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Biopharmaceutical Companies
13.4.2. Pharmaceutical Companies
13.4.3. Research Organizations
13.4.4. Others
13.5. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, , By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
13.7. Latin America Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
14.1. Manufacturing Process Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Mammalian Based
14.1.2. Microbial Based
14.1.3. Insect Based
14.1.4. Plant Based
14.1.5. Yeast Based
14.1.6. Others
14.2. Type of Service Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Formulation
14.2.2. Fill and Finish services
14.2.3. Cell Banking
14.2.4. Analytical Services
14.2.5. Process development
14.2.6. Others
14.3. Molecule Type Analysis, 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.3.1. Large Molecules
14.3.2. Small Molecules
14.4. End -Use Analysis, 2012- 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.4.1. Biopharmaceutical Companies
14.4.2. Pharmaceutical Companies
14.4.3. Research Organizations
14.4.4. Others
14.5. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Biopharmaceutical Contract Manufacturing Market - Opportunity Analysis Index, , By Manufacturing Process, By Type of Service, By Molecule Type, By End –Use and Country, 2017 – 2023
14.7. MEA Biopharmaceutical Contract Manufacturing Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Lonza Group Ltd. (Switzerland)
15.2.2. Boehringer Ingelheim GmbH (Germany)
15.2.3. Charles River Laboratories, Inc. (U.S)
15.2.4. Novartis AG (Switzerland)
15.2.5. WuXi AppTec Group (China)
15.2.6. Rentschler Biotechnologie GmbH (Germany)
15.2.7. Fujifilm Holdings Corporation (Japan)
15.2.8. Celonic AG (Switzerland)
15.2.9. BIOMEVA GmbH (Germany)
15.2.10. ProBioGen AG (Germany)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
